Crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor
The present disclosure relates to a novel crystalline form of a tosylate of diazadicyclic compound of formula (I), preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a drug for treating alopecia areata, psoriasis and ulcerative colitis.
1 . A crystalline Form A of a tosylate of a compound of formula (I) ((1S)-2,2-difluorocyclo-propyl) ((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone, wherein the crystalline Form A is characterized by a reflection X-ray powder diffraction pattern (Cu-Kα radiation) comprising characteristic diffraction peaks at angles (2θ) of 6.2°±0.2° 2θ, 9.3°±0.2° 2θ, and 18.6°±0.2° 2θ,
2 . A process for preparing the crystalline Form A according to claim 1 , wherein the process comprises,
dissolving formula (I) tosylate into a solvent, filtering, and quickly adding the filtrate into an anti-solvent to obtain the crystalline Form A.
3 . A pharmaceutical composition, wherein said pharmaceutical composition comprises the crystalline Form A according to claim 1 and pharmaceutically acceptable carriers.